Completed PHASE1/PHASE2 INTERVENTIONAL NCT00140374

Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)

Phase I/II Study of Vaccination Priming and Vaccine Boosting With Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines in Patients With Prostate Cancer

Sponsor: Cell Genesys

Conditions Prostate Cancer

Interventions Immunotherapy allogeneic GM-CSF secreting cellular vaccine

Updated 5 times since 2017 Last updated: Aug 30, 2005 Started: Dec 31, 1998 Completion: Feb 28, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by Cell Genesys and has accumulated 5 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

First recorded

Dec 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cell Genesys

Data source: Cell Genesys

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.